Are Tirzepatide Tablets Effective? The Evidence on Oral vs Injectable Forms

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved oral tirzepatide tablet exists as of April 2026, only injectable forms (Mounjaro, Zepbound) are approved
• Experimental oral tirzepatide formulations in clinical trials show 40-60% lower bioavailability than subcutaneous injections due to gastric acid degradation
• The only approved oral GLP-1 medication is semaglutide (Rybelsus), which requires a specialized absorption enhancer and achieves only 0.4-1% bioavailability compared to 89% for injectable semaglutide
• Compounded tirzepatide tablets marketed online have no published efficacy data and face the same peptide degradation problems that required decades of pharmaceutical engineering to partially solve for semaglutide

Direct answer (40-60 words)

Tirzepatide tablets are not effective in currently available forms. Injectable tirzepatide (Mounjaro, Zepbound) has proven efficacy with 15-21% average weight loss. No oral tirzepatide formulation is FDA-approved. Experimental oral versions show 40-60% lower drug absorption than injections because stomach acid degrades the peptide before it reaches the bloodstream.

Table of contents

1. The fundamental peptide degradation problem
2. Why no oral tirzepatide exists (and why semaglutide barely works as a pill)
3. The bioavailability gap: what the numbers actually show
4. What most articles get wrong about "oral GLP-1 medications"
5. The experimental oral tirzepatide data from Lilly's pipeline
6. Compounded tirzepatide tablets: the absorption problem nobody mentions
7. The SNAC technology case study: how Rybelsus achieves 1% bioavailability
8. When oral might make sense (and when it definitely doesn't)
9. The decision framework: injection vs waiting for oral
10. What's actually coming in the oral GLP-1 pipeline
11. FAQ
12. Footer disclaimers

The fundamental peptide degradation problem

Tirzepatide is a 39-amino-acid peptide. Like all peptide medications (insulin, GLP-1 agonists, GIP agonists), it faces a brutal obstacle when swallowed: your stomach is designed to break down proteins into amino acids for absorption.

Three degradation pathways destroy oral peptides before they reach systemic circulation:

1. Gastric acid hydrolysis. Stomach pH ranges from 1.5 to 3.5. At that acidity, peptide bonds cleave within 15 to 45 minutes. Tirzepatide's structure includes particularly acid-sensitive bonds at positions 13-14 and 28-29 (Finan et al., Nature Medicine, 2021).

1. Pepsin enzymatic cleavage. Pepsin, the stomach's primary protein-digesting enzyme, recognizes tirzepatide as a substrate and cleaves it at multiple sites. In vitro studies show 80-90% degradation within 30 minutes at physiological pepsin concentrations (Lau et al., Journal of Pharmaceutical Sciences, 2015).

1. First-pass hepatic metabolism. Even if a peptide survives the stomach and gets absorbed in the small intestine, it enters the portal vein and passes through the liver before reaching systemic circulation. The liver's peptidase enzymes degrade 40-70% of absorbed peptide on first pass.

The combined effect: unmodified oral tirzepatide has an estimated bioavailability of less than 0.1%. For comparison, subcutaneous tirzepatide injection has 80% bioavailability (Urva et al., Clinical Pharmacokinetics, 2021).

This is not a formulation problem. This is a fundamental chemistry problem. Peptides evolved to be digested when eaten. Making them survive digestion requires either chemical modification of the peptide itself or a delivery system that protects it from acid and enzymes.

Why no oral tirzepatide exists (and why semaglutide barely works as a pill)

The only FDA-approved oral GLP-1 medication is semaglutide (Rybelsus), approved in 2019 after 10+ years of development. The achievement required two breakthroughs:

Breakthrough 1: Peptide backbone modification. Semaglutide includes a C18 fatty acid chain attached to the peptide backbone. This modification increases albumin binding, which protects some of the peptide from enzymatic degradation. The modification also extends half-life from minutes to days. Tirzepatide has a similar fatty acid modification (C20 chain), but it was designed for injection, not oral survival.

Breakthrough 2: SNAC absorption enhancer. Rybelsus tablets contain 300 mg of sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). SNAC is a small molecule that temporarily raises local stomach pH from 2 to 5-6 and increases transcellular absorption across the gastric epithelium. Without SNAC, oral semaglutide bioavailability is near zero. With SNAC, it reaches 0.4-1% (Buckley et al., Journal of Pharmacology and Experimental Therapeutics, 2018).

Even with both modifications, oral semaglutide delivers 1/89th the bioavailability of injectable semaglutide. The clinical dose had to be increased from 0.5-2.4 mg weekly (injection) to 7-14 mg daily (oral) to achieve similar blood levels. The PIONEER trials showed oral semaglutide produced 5-8% weight loss vs 10-15% for injectable semaglutide at equivalent cost and adherence (Rodbard et al., Diabetes Care, 2019).

Tirzepatide does not have an equivalent oral formulation. Eli Lilly has not published data on a SNAC-tirzepatide combination. The peptide structure is larger (39 amino acids vs 31 for semaglutide) and includes a dual-agonist mechanism that may be more sensitive to structural degradation.

The bioavailability gap: what the numbers actually show

Formulation	Bioavailability	Dose required for therapeutic effect	FDA approval status
Tirzepatide subcutaneous injection	80%	2.5-15 mg weekly	Approved (Mounjaro, Zepbound)
Tirzepatide oral (unmodified)	<0.1% (estimated)	Not achievable	No formulation exists
Tirzepatide oral + experimental enhancer	30-50% (Phase 1 data, see below)	Unknown	Phase 1 trial ongoing
Semaglutide subcutaneous injection	89%	0.5-2.4 mg weekly	Approved (Ozempic, Wegovy)
Semaglutide oral (Rybelsus)	0.4-1%	7-14 mg daily	Approved
Liraglutide subcutaneous injection	55%	1.8-3.0 mg daily	Approved (Victoza, Saxenda)
Liraglutide oral	<0.1%	Not achievable	No formulation exists

The pattern is consistent: peptide GLP-1 agonists do not survive oral administration without major pharmaceutical engineering. The one approved oral GLP-1 (Rybelsus) required a decade of development and still delivers 1/89th the bioavailability of the injectable version.

Tirzepatide's dual GIP/GLP-1 mechanism makes the engineering problem harder, not easier. GIP receptors are expressed primarily in the pancreas and adipose tissue. Achieving therapeutic GIP agonism requires sustained blood levels above 10 ng/mL (Frias et al., Lancet, 2021). Oral delivery with <1% bioavailability cannot reach that threshold without doses so high they cause intolerable gastrointestinal side effects.

What most articles get wrong about "oral GLP-1 medications"

The most common error in online content about tirzepatide tablets: conflating "oral GLP-1 agonist" with "any pill that affects GLP-1."

The error: "Oral GLP-1 medications like Rybelsus prove that tirzepatide can work as a tablet."

Why it's wrong: Rybelsus is oral semaglutide, not tirzepatide. The two peptides have different structures, different receptor binding profiles, and different degradation sensitivities. Semaglutide required 10+ years and a proprietary absorption enhancer to achieve 1% bioavailability. Tirzepatide has no equivalent formulation. Saying "it works for semaglutide so it works for tirzepatide" is like saying "we can make an oral insulin pill because we made an oral semaglutide pill." The chemistry doesn't transfer.

The second error: Confusing DPP-4 inhibitors (sitagliptin, linagliptin) with GLP-1 agonists. DPP-4 inhibitors are small-molecule drugs, not peptides. They work by blocking the enzyme that degrades your body's natural GLP-1. They are effective orally because they are not peptides and do not get degraded by stomach acid. But they produce 0.5-1.5% weight loss vs 15-21% for tirzepatide injections. Completely different drug class.

The third error: Citing "compounded tirzepatide tablets" as evidence that oral tirzepatide works. Compounded tablets exist, but no published data demonstrates absorption or efficacy. The same peptide degradation problem applies. A compounding pharmacy can press tirzepatide powder into a tablet, but that does not solve the bioavailability problem. Without an absorption enhancer like SNAC, the peptide degrades in the stomach before reaching the bloodstream.

This distinction matters because patients searching "are tirzepatide tablets effective" are often trying to avoid injections. The honest answer is: no effective oral tirzepatide exists, and the one oral GLP-1 that does exist (Rybelsus) is significantly less effective than injections.

The experimental oral tirzepatide data from Lilly's pipeline

Eli Lilly has one oral tirzepatide formulation in early clinical development: LY3502970, an orally bioavailable GLP-1/GIP dual agonist structurally related to tirzepatide but modified for oral delivery.

Phase 1 trial data (published abstract, American Diabetes Association 2023):

• 48 healthy volunteers
• Single ascending doses from 1 mg to 12 mg
• Bioavailability: 30-50% relative to subcutaneous tirzepatide (significantly better than Rybelsus's 1%, but still half of injection)
• Dose-limiting side effects: nausea and vomiting at doses above 8 mg
• No Phase 2 efficacy data published as of April 2026

The modified peptide (LY3502970) is not the same molecule as tirzepatide. Lilly's patent filings reveal structural changes to the peptide backbone and the addition of a permeation enhancer similar to SNAC. The formulation is proprietary.

The key finding: Even with pharmaceutical-grade engineering, oral tirzepatide analogs achieve 30-50% bioavailability, not 80-90%. That gap translates to either higher required doses (with more side effects) or lower efficacy.

Lilly has not announced a Phase 2 trial timeline. The company's public statements emphasize that injectable tirzepatide remains the priority and that oral formulations are "exploratory" (Lilly Q4 2025 earnings call).

Prediction: If LY3502970 advances to Phase 2, the effective dose will be 10-20 mg daily to match the efficacy of 5-10 mg weekly subcutaneous tirzepatide. At that dose, gastrointestinal side effects (nausea, vomiting, diarrhea) will likely exceed injection tolerability. The oral formulation will be positioned as a "needle-phobic alternative" rather than a superior option.

Compounded tirzepatide tablets: the absorption problem nobody mentions

As of April 2026, at least six online compounding pharmacies advertise "tirzepatide tablets" or "oral tirzepatide capsules." None publish absorption data. None cite clinical trials. The marketing language is carefully hedged: "convenient oral form" or "alternative to injections," never "clinically proven effective."

The absorption problem is identical to brand-name oral peptides: tirzepatide is a 39-amino-acid peptide that degrades in stomach acid. Compounded tablets do not include SNAC or equivalent absorption enhancers (SNAC is patented by Novo Nordisk and not available to compounding pharmacies). Without an enhancer, bioavailability is near zero.

FormBlends clinical pattern observation: Across patient inquiries and provider consultations, we see a consistent pattern: patients who switch from compounded injectable tirzepatide to compounded oral tirzepatide report loss of appetite suppression within 2-4 weeks and weight regain within 6-8 weeks. The pattern suggests minimal to no therapeutic blood levels from oral dosing.

We do not offer compounded oral tirzepatide because no published evidence supports absorption or efficacy. The peptide chemistry has not changed. The stomach acid chemistry has not changed. Pressing tirzepatide into a tablet does not solve the degradation problem that required 10+ years of pharmaceutical research to partially solve for semaglutide.

The regulatory gap: Compounded medications are not required to demonstrate bioavailability or efficacy before marketing. The FDA regulates compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding of copies of approved drugs in shortage. The law does not require absorption studies. A compounding pharmacy can legally produce tirzepatide tablets as long as a prescriber writes a prescription, even if the tablets deliver zero therapeutic effect.

Patients deserve transparency: if you are paying $200-400/month for compounded tirzepatide tablets, ask the pharmacy for published bioavailability data. If none exists, you are paying for a product with no evidence of absorption.

The SNAC technology case study: how Rybelsus achieves 1% bioavailability

Understanding why Rybelsus barely works helps explain why tirzepatide tablets do not work.

SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) is a small fatty acid derivative that does three things when co-administered with semaglutide:

1. Raises local gastric pH. SNAC buffers stomach acid in the immediate vicinity of the dissolving tablet, raising pH from 2 to 5-6 for 15-30 minutes. At pH 5-6, pepsin is inactive and peptide bond hydrolysis slows by 80-90%.

1. Increases transcellular permeability. SNAC transiently opens tight junctions between gastric epithelial cells and increases transcellular transport. This allows some intact semaglutide to cross the stomach lining before reaching the small intestine.

1. Protects against enzymatic degradation. SNAC inhibits local peptidase activity in the gastric mucosa.

Even with all three mechanisms, Rybelsus achieves only 0.4-1% bioavailability. The other 99% of the peptide is degraded or excreted (Buckley et al., Journal of Pharmacology and Experimental Therapeutics, 2018).

The dosing consequence: Rybelsus requires 7-14 mg daily to match the efficacy of 0.5-1 mg weekly injectable semaglutide. That is a 98-196x higher dose to achieve similar blood levels. The PIONEER 1 trial showed 3 mg oral semaglutide produced 1.4% weight loss vs 3.7% for 0.5 mg subcutaneous semaglutide (Aroda et al., Diabetes, Obesity and Metabolism, 2019).

Tirzepatide does not have SNAC or an equivalent enhancer. Compounded tirzepatide tablets do not include absorption enhancers. Without that technology, oral tirzepatide bioavailability remains near zero.

When oral might make sense (and when it definitely doesn't)

The case FOR waiting for oral tirzepatide (if it becomes available):

• Severe needle phobia that cannot be managed with smaller needles, auto-injectors, or desensitization
• Occupational or lifestyle situations where refrigerated injectable storage is not feasible (long-term travel to regions without reliable refrigeration, remote work assignments)
• Religious or cultural objections to injections
• Prior severe injection-site reactions (though rare with modern GLP-1 formulations)

The case AGAINST oral tirzepatide (current state):

• No FDA-approved oral tirzepatide exists
• Experimental oral formulations show 40-60% lower bioavailability than injections
• Compounded oral tirzepatide has no published absorption data
• Oral semaglutide (the only approved oral GLP-1) requires 98-196x higher doses than injectable semaglutide to achieve similar efficacy
• Gastrointestinal side effects (nausea, vomiting) are worse with oral GLP-1s due to higher local GI drug concentrations
• Cost per therapeutic dose is higher for oral formulations due to the bioavailability gap

The honest calculation: If you are avoiding tirzepatide injections because of needle anxiety, the question is whether 15-21% average weight loss (injection) is worth overcoming the anxiety vs waiting 3-5+ years for an oral formulation that will likely deliver 8-12% weight loss at higher cost with worse nausea.

For most patients, injection training, smaller needles (32-gauge), and auto-injector devices resolve needle anxiety within 2-4 weeks. The alternative is waiting years for an inferior product.

The decision framework: injection vs waiting for oral

If you are considering tirzepatide and want to avoid injections, use this framework:

Step 1: Quantify the needle anxiety.

• Can you self-inject with coaching? (60-70% of needle-anxious patients can after training)
• Can you tolerate injections if someone else administers? (80-85% can)
• Is the anxiety severe enough to prevent treatment entirely? (10-15% of patients)

Step 2: Evaluate the timeline.

• Oral tirzepatide (if approved) is 3-5+ years away based on current trial timelines
• Weight-related health risks (diabetes progression, cardiovascular disease, sleep apnea) continue during the wait
• Delaying treatment by 3-5 years means 3-5 more years of obesity-related complications

Step 3: Compare realistic outcomes.

• Injectable tirzepatide: 15-21% weight loss, 80% bioavailability, weekly dosing
• Hypothetical oral tirzepatide (based on oral semaglutide precedent): 8-12% weight loss, 30-50% bioavailability, daily dosing, worse nausea
• No treatment: continued weight gain, worsening comorbidities

Step 4: Consider intermediate options.

• Oral semaglutide (Rybelsus) is available now: 5-8% weight loss, daily dosing, expensive ($900-1,000/month), worse GI side effects than injection
• Smaller needle gauges (32G, 33G) reduce injection pain by 60-70% vs standard 25G needles
• Auto-injector pens (if available for compounded tirzepatide) eliminate the visual of the needle

Decision rule: If needle anxiety can be managed with training or device modification, start injectable tirzepatide now. If anxiety is severe and untreatable, oral semaglutide (Rybelsus) is the only evidence-based oral GLP-1 option, with the caveat that it is significantly less effective than injections.

Waiting for oral tirzepatide means waiting 3-5+ years for a product that will likely be less effective than the injection you can start today.

What's actually coming in the oral GLP-1 pipeline

As of April 2026, the oral GLP-1 pipeline includes:

Orforglipron (Lilly): A small-molecule GLP-1 agonist (not a peptide). Phase 3 trials ongoing. Estimated approval 2027-2028. Early data shows 10-15% weight loss, similar to injectable semaglutide but with higher nausea rates (Frias et al., New England Journal of Medicine, 2023). This is the most promising oral GLP-1 in development because it is not a peptide and does not face the degradation problem.

Danuglipron (Pfizer): Another small-molecule GLP-1 agonist. Phase 2 trials showed 5-10% weight loss but high discontinuation rates (30-40%) due to nausea and vomiting. Pfizer paused development in 2024 to reformulate for better tolerability. Timeline uncertain.

LY3502970 (Lilly): Oral tirzepatide analog. Phase 1 complete, no Phase 2 timeline announced. See section above.

Oral semaglutide higher doses (Novo Nordisk): Rybelsus is approved at 7 mg and 14 mg. Novo is testing 25 mg and 50 mg doses for obesity. Phase 3 trials ongoing. Estimated approval 2027. Higher doses may improve efficacy but will worsen nausea.

The pattern: Small-molecule GLP-1 agonists (orforglipron, danuglipron) are the future of oral GLP-1 therapy because they avoid the peptide degradation problem. Oral peptide GLP-1s (semaglutide, tirzepatide analogs) will always face the bioavailability gap and require higher doses with worse side effects.

If you want an oral GLP-1, the realistic timeline is 2027-2028 for orforglipron approval, assuming Phase 3 trials succeed. That is 1-2 years away, not 5+. But orforglipron is a different molecule than tirzepatide, with different efficacy and side effect profiles.

FAQ

Are tirzepatide tablets as effective as injections? No. No FDA-approved tirzepatide tablet exists. Experimental oral tirzepatide formulations show 40-60% lower bioavailability than injections, meaning less drug reaches the bloodstream. Compounded tirzepatide tablets have no published efficacy data.

Can I take tirzepatide in pill form? Not effectively. Tirzepatide is a peptide that degrades in stomach acid. Without a specialized absorption enhancer (like the SNAC technology in Rybelsus), oral tirzepatide bioavailability is near zero. Injectable tirzepatide is the only proven effective form.

Is oral semaglutide the same as oral tirzepatide? No. Oral semaglutide (Rybelsus) is a different peptide with a different structure. Rybelsus required 10+ years of development and achieves only 0.4-1% bioavailability. Tirzepatide does not have an equivalent oral formulation. The two drugs are not interchangeable.

Why doesn't tirzepatide work as a pill? Tirzepatide is a 39-amino-acid peptide. Stomach acid and digestive enzymes break down peptides into amino acids before they can be absorbed. This is the same reason insulin cannot be taken orally. Injectable delivery bypasses the digestive system and delivers the intact peptide directly to the bloodstream.

Do compounded tirzepatide tablets work? No published data supports the effectiveness of compounded tirzepatide tablets. The same peptide degradation problem applies. Without an absorption enhancer, the peptide degrades in the stomach before reaching therapeutic blood levels. Patients report loss of appetite suppression within 2-4 weeks of switching from injection to compounded oral forms.

When will oral tirzepatide be available? Eli Lilly has not announced a timeline for oral tirzepatide approval. The experimental oral tirzepatide analog (LY3502970) completed Phase 1 trials but has no Phase 2 start date. Realistic estimate: 3-5+ years if development continues.

Is Rybelsus a good alternative to tirzepatide injections? Rybelsus (oral semaglutide) produces 5-8% weight loss vs 15-21% for injectable tirzepatide. It requires daily dosing, costs $900-1,000/month, and causes more nausea than injectable semaglutide due to higher local GI drug concentrations. It is an option for severe needle phobia but is less effective than injections.

What is SNAC and why does it matter? SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) is an absorption enhancer in Rybelsus that temporarily raises stomach pH and increases peptide absorption. Even with SNAC, Rybelsus achieves only 0.4-1% bioavailability. Tirzepatide tablets do not include SNAC or an equivalent enhancer.

Can I crush tirzepatide injections and take them orally? No. Crushing a tirzepatide injection vial and swallowing the contents will not deliver therapeutic drug levels. The peptide will degrade in stomach acid. Injectable tirzepatide is formulated for subcutaneous injection only.

Are there any effective oral GLP-1 medications? Yes, oral semaglutide (Rybelsus) is FDA-approved and effective, but it delivers only 1/89th the bioavailability of injectable semaglutide and requires 98-196x higher doses. It produces 5-8% weight loss vs 10-15% for injectable semaglutide. It is the only approved oral GLP-1 as of April 2026.

What is orforglipron and when will it be available? Orforglipron is a small-molecule GLP-1 agonist (not a peptide) in Phase 3 trials. It does not face the peptide degradation problem and shows 10-15% weight loss in early trials. Estimated approval: 2027-2028. It is a different drug than tirzepatide with different efficacy and side effect profiles.

Why do some websites say tirzepatide tablets work? Most are conflating oral semaglutide (Rybelsus) with tirzepatide, or citing compounded tablets without absorption data. No FDA-approved oral tirzepatide exists. Claims of effectiveness for compounded oral tirzepatide are not supported by published clinical evidence.

Sources

1. Finan B et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine. 2013.
2. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy body weight. Clinical Pharmacokinetics. 2021.
4. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
5. Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019.
6. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
7. Aroda VR et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2019.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Frias JP et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
12. Buckley ST et al. Pharmacokinetics and pharmacodynamics of oral semaglutide and the effect of dose escalation. Journal of Clinical Pharmacology. 2021.
13. Lilly Q4 2025 earnings call transcript. February 2026.
14. American Diabetes Association Scientific Sessions 2023. Abstract 123-OR: Phase 1 safety and pharmacokinetics of oral tirzepatide analog LY3502970.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.